高危上尿路尿路上皮癌伴ERBB2基因突变对铂类全身化疗近完全缓解一例报告
本文报告一例54岁女性转移性上尿路尿路上皮癌(UTUC)患者,接受顺铂联合吉西他滨全身化疗后影像示肾盂肾盏肿块及腹膜后淋巴结均缩小,巩固性切除标本仅见3 mm残留肾肿瘤、淋巴结无存活肿瘤,基因组检测发现ERBB2功能获得性突变。
要点
- 转移性UTUC伴ERBB2功能获得性突变者对顺铂联合吉西他滨化疗反应良好。
- 化疗后影像示肾盂肾盏肿块缩小、腹膜后淋巴结缩小(与初诊影像相比)。
- 巩固性手术病理示3 mm残留肾肿瘤,淋巴结无存活肿瘤。
核心结论
- 转移性UTUC伴ERBB2突变者接受顺铂为基础化疗可获得近完全缓解,术后仅见3 mm残留肾肿瘤且淋巴结无存活肿瘤。
研究设计与样本
- 个案报告:54岁女性转移性上尿路尿路上皮癌患者,接受顺铂联合吉西他滨全身化疗后行巩固性切除。
主要发现
- 化疗后影像示肾盂肾盏肿块缩小、腹膜后淋巴结较初诊影像缩小。
- 巩固性切除病理示3 mm残留肾肿瘤,淋巴结无存活肿瘤。
- 基因组检测示ERBB2功能获得性突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为个案报告,ERBB2突变与铂类化疗疗效的关联在UTUC中尚未见报道,尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In bladder urothelial carcinoma, ERBB2 mutations have been associated with favorable response to platinum-based neoadjuvant chemotherapy. However, this association has not been reported in upper tract urothelial carcinoma (UTUC). We describe an excellent response to cisplatin-based chemotherapy in metastatic UTUC with an ERBB2 mutation. Our patient is a 54-year-old female with metastatic UTUC who received systemic cisplatin and gemcitabine. Postchemotherapy imaging demonstrated decreased size of pyelocaliceal mass and decreased retroperitoneal adenopathy compared to initial imaging. Surgical pathology from consolidative resection showed 3 mm residual renal tumor and no viable lymph node disease. Genomic testing demonstrated an ERBB2 gain of function mutation.
引用
- Weiss K, Abimbola O, Miller K, et al. Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report. Urology. 2023. PMID: 38052324. doi:10.1016/j.urology.2023.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。